Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic ...

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Ahead of the BIOSECURE Act, WuXi AppTec is in talks to sell its Philadelphia-based cell and gene therapy unit, and WuXi ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

Today, FMI President and CEO Leslie Sarasin issued the following statement: "Shoppers may be worried about their grocery needs due to the ongoing strike by the International Longshoremen's Association ...